Browsing Category
Featured Articles
Sanofi to create new industry leading European company to provide API
Sanofi plans to create a major leading European company dedicated to the production and marketing to third parties of active pharmaceutical ingredients (API), which are the essential…
Read More...
Read More...
Comar to Expand West Coast Footprint
Comar, a specialty packaging, device, and component supplier serving the Medical, Pharmaceutical, Consumer Healthcare, Personal and Home Care, Food and Beverage, and other niche market…
Read More...
Read More...
Regeneron Announces Expanded Collaboration with HHS to Develop Antibody Treatments for New…
Regeneron Pharmaceuticals announced an expanded agreement with the U.S. Department of Health and Human Services (HHS) to develop new treatments combating the novel coronavirus,…
Read More...
Read More...
Johnson & Johnson Launches Multi-Pronged Response to Coronavirus Global Public Health Threat
Johnson & Johnson announced that it is mobilizing resources at its Janssen Pharmaceutical Companies to launch a multi-pronged response to the novel coronavirus (also known as…
Read More...
Read More...
Sandoz completes acquisition of Aspen’s Japanese operations
Sandoz announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen Pharmacare Holdings…
Read More...
Read More...
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) for selpercatinib (LOXO-292), for the…
Read More...
Read More...
AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep
AbbVie and Allergan announced that Allergan has entered into definitive agreements to divest brazikumab (IL-23 inhibitor) and Zenpep (pancrelipase). These agreements are in conjunction…
Read More...
Read More...
BMS secures FDA priority review for NSCLC treatment combination
Bristol-Myers Squibb Company announced the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in…
Read More...
Read More...
MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab
MorphoSys AG and Incyte Corporation announced that the companies have entered into a collaboration and license agreement to further develop and commercialize MorphoSys' proprietary…
Read More...
Read More...
Lilly Announces Agreement to Acquire Dermira
Eli Lilly and Company and Dermira, Inc. announced a definitive agreement for Lilly to acquire Dermira for $18.75 per share, or approximately $1.1 billion, in an all-cash transaction.…
Read More...
Read More...
FDA approves Fiasp for treatment of children with diabetes
Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved Fiasp (insulin aspart injection) 100 u/mL for use as a new mealtime insulin option for children with…
Read More...
Read More...
Merck Establishes Strategic Oncology Collaboration with Taiho and Astex
Merck, known as MSD outside the United States and Canada, announced an exclusive worldwide research collaboration and license agreement with Taiho Pharmaceutical Co, Ltd., (“Taiho”) and…
Read More...
Read More...
Charles River Laboratories Completes the Acquisition of HemaCare Corporation
Charles River Laboratories International announced that it has completed the previously announced acquisition of HemaCare Corporation for approximately $380 million in cash, or $25.40…
Read More...
Read More...
UMass Medical School, GE Healthcare Life Sciences to establish viral vector manufacturing facility
UMass Medical School and GE Healthcare Life Sciences will establish a new large-scale viral vector manufacturing facility, able to provide large quantities of high-quality recombinant…
Read More...
Read More...
Boehringer and Lilly provide update on Jardiance phase III exercise ability studies in chronic heart…
Boehringer Ingelheim and Eli Lilly and Company announced results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials related to functional endpoints with Jardiance (empagliflozin)…
Read More...
Read More...
Regeneron and Sanofi Announce Intent to Restructure Antibody Collaboration for Kevzara and Praluent
Regeneron Pharmaceuticals and Sanofi announced their intent to simplify their antibody collaboration for Kevzara (sarilumab) and Praluent (alirocumab) by restructuring into a…
Read More...
Read More...
Amneal to Acquire Majority Interest in AvKARE, Enhancing Access to Growing Federal Healthcare Market
Amneal Pharmaceuticals, Inc. and AvKARE Inc. announced they have entered into a definitive agreement under which Amneal will acquire a 65.1% majority interest in AvKARE and its related…
Read More...
Read More...
Leo Pharma’s tralokinumab meets key endpoints in phase 3 atopic dermatitis trials
LEO Pharma A/S announced that tralokinumab – an investigational, fully human monoclonal antibody that specifically neutralizes the interleukin-13 (IL-13) cytokine – met all primary and…
Read More...
Read More...
AbbVie and Scripps Research announce collaboration to develop a broad range of new therapeutics
AbbVie, a research-based global biopharmaceutical company and Scripps Research, an international leader in non-profit biomedical research and drug discovery, announced a collaboration…
Read More...
Read More...
Healx Joins Forces With Boehringer To Discover New Treatment Approaches For Rare Neurological…
Healx Ltd., the AI-powered biotechnology company focused on developing breakthrough treatments for rare diseases, announces it has entered into an agreement with Boehringer Ingelheim to…
Read More...
Read More...